Bionano Genomics 

€0
0
-€315.84-100% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13MayExpected
Q4 2025
Next
-2.13
-1.67
-1.21
-0.75
Expected EPS
-0.750464
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 2Y30.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pacific Biosciences of California
PACB
Mkt Cap404.68M
Pacific Biosciences offers long-read sequencing technologies that compete with Bionano's optical genome mapping solutions for complex genetic research and diagnostics.
Illumina
ILMN
Mkt Cap19.48B
Illumina provides sequencing and array-based solutions for genetic analysis, directly competing in the genomics market space that Bionano targets.
Thermo Fisher Scientific
TMO
Mkt Cap182.57B
Thermo Fisher Scientific offers a broad range of instruments and reagents for genomic research, including next-generation sequencing, competing with Bionano's genomic analysis technologies.
Agenus
AGEN
Mkt Cap127.87M
Agilent Technologies provides instruments, software, services, and consumables for the entire laboratory workflow, including genomics research, competing with Bionano's offerings.
Qiagen NV
QGEN
Mkt Cap8.46B
Qiagen offers sample to insight solutions, including next-generation sequencing and molecular diagnostics that compete with Bionano's genomic analysis solutions.
Intellia Therapeutics
NTLA
Mkt Cap1.55B
Intellia Therapeutics is involved in CRISPR/Cas9 technology for genome editing, which competes indirectly with Bionano's genomic mapping and analysis technologies by offering alternative approaches to genetic research and diagnostics.
Editas Medicine
EDIT
Mkt Cap261.32M
Editas Medicine operates in the genome editing space using CRISPR technology, offering a competitive alternative to Bionano's genomic analysis and mapping solutions.
CRISPR Therapeutics
CRSP
Mkt Cap4.75B
CRISPR Therapeutics is focused on developing gene-based medicines using CRISPR/Cas9 technologies, indirectly competing with Bionano's genomic analysis tools by providing alternative methods for genetic research.
Twist Bioscience
TWST
Mkt Cap3.08B
Twist Bioscience operates in the synthetic biology and genomics field, producing synthetic DNA that is used in genetic research, competing with Bionano's genomic analysis and mapping technologies.

About

Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
Show more...
CEO
Dr. Robert Erik Holmlin M.B.A., Ph.D.
Employees
98
Country
United States
ISIN
US09075F4046

Listings

0 Comments

Share your thoughts

FAQ

What is Bionano Genomics stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Bionano Genomics stocks are traded under the ticker 2Y30.STU.
Is Bionano Genomics stock price growing?
2Y30.STU stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Bionano Genomics has showed a +0% increase.
When is the next Bionano Genomics earnings date?
Bionano Genomics is going to release the next earnings report on May 13, 2026.
What were Bionano Genomics earnings last quarter?
2Y30.STU earnings for the last quarter are -2 EUR per share, whereas the estimation was -2.13 EUR resulting in a +6.26% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Bionano Genomics have?
As of April 11, 2026, the company has 98 employees.
In which sector is Bionano Genomics located?
Bionano Genomics operates in the Health & Wellness sector.
When did Bionano Genomics complete a stock split?
Bionano Genomics has not had any recent stock splits.
Where is Bionano Genomics headquartered?
Bionano Genomics is headquartered in San Diego, United States.